Replies to post #123402 on Value Microcaps Motherboard

[Knowledge is King]

re NZYM: I listened to the call...

Overall, certainly no need to run out and buy the stock for awhile. However, there were some positives:

-backlog rose sequentially from $1.9M to $2.7M

-Q3 book-to-bill was 1.33 ($3.2M in orders vs $2.4 in revenues)

-Q4 profitability should be at least $.01/share if they hit their forecast of FY10 earnings matching FY09

-they described the disappointing Q3 results as "quite an anomaly" and blamed the disruptive impact of "the healthcare initiative"

-they seemed quite optimistic about their new research center in San Diego, which will be fully operational in the June quarter. It's designed to serve low-volume, rapid turnaround clients

Summing up, with a book value of $.72/share, expected FY10 EPS of $.08, and past earnings power of $.05-.07 quarterly, I view NZYM shares as undervalued at current prices.

As for HepC, there was little commentary positive or negative, IMO.